

Inflation accelerates on the back of food and tobacco prices in January

Consumer prices rose by 1.65% mom in January, exceeding both our forecast of 1.35% and consensus of 1.12%. Thus, annual inflation jumped to 7.3% in January, from 6.2% by YE12.

- **The acceleration in inflation stemmed from price adjustments to tobacco, along with a surge in food prices.** Tobacco prices increased by 15% mom, following the tax hike as of January, contributing 0.7pp to the headline inflation. Food prices, particularly unprocessed food, soared by 4% mom in January, well beyond even our above-consensus forecast of 2.1%. Hence, the favourable trend in food inflation, which backed the disinflation trend throughout the year 2012, has shifted course as of January. Annual food inflation accelerated to 6.9% in Jan'13 from 3.9% in Dec'12.
- On the other hand, **the downward trend in core inflation seems intact.** Core inflation I (excluding food, energy, alcohol, tobacco and gold) decelerated slightly to 5.7% from 5.8% in December. The deceleration has actually proved short of our expectations, mostly due to a somewhat milder-than-forecast seasonal drop in clothing prices. Despite the CBT's guidance of below 5% core inflation for YE13, we remain cautious on the back of an expected revival in domestic demand in 2013.

Regarding monetary policy, the CBT had already cautioned about a possible jump in unprocessed food prices and in headline inflation in January, in the latest MPC meeting minutes last week. Hence, we do **not expect any changes to the monetary stance** following today's inflation print. Monetary policy is currently being shaped by the real performance of the TRL and the course of loan growth. Real effective exchange rate (REER) for January will be announced tomorrow at 2:30 pm. local time. According to our calculations, **REER will have been around 120.5 in January**, moving beyond the 120 threshold into overvalued territory. The CBT has already acted in January, by cutting the lower band by 25bp to 4.75%. The thing is the TRL is currently trading at 2.0640 against the currency basket, and our calculations suggest the **REER may remain above the 120 mark in February as well, which might trigger another 25bp cut in the lower band** in February, if sustained until the MPC meeting. Note that a cut at the lower band is aimed solely at deterring capital inflows, and is not expected to provide any additional stimulus to economic activity. Otherwise, we expect the CBT to maintain the policy rate and the upper band of the corridor, as well as the RRRs unchanged at the February meeting at this stage.

Haluk Burumcekci
Chief Economist

+90 212 317 2737

haluk.burumcekci@burgansecurities.com

Asli Savranoglu Seren
Senior Economist

+90 212 317 2866

asli.savranoglu@burgansecurities.com



Buyukdere Cad.
Apa Giz Plaza
No: 191 Levent, Istanbul
Tel: +90 212 317 2727
Fax: +90 212 317 2726
info@burgansecurities.com

Burgan Securities (formerly EFG Istanbul Equities) is a prominent investment firm active in the fields of brokerage, corporate finance and asset management in Turkish capital markets. Our firm, a member of Burgan Group, one of the leading financial institutions of Kuwait, caters to the entirety of domestic/international retail/institutional investor spectrum. Supporting our corporate finance and institutional sales activities is a highly qualified research team that offers premium quality and timely research products covering a broad array of sectors and companies. Our corporate finance activities comprise mergers and acquisitions, as well as private and public equity and debt transactions. Our new product development activities are centred around derivative products, along with online trading platforms for retail clients.

Burgan Securities' goal is to be the investment firm of choice in Turkey through exemplary service and product quality, with a view to becoming a regional player.

Mehmet Sonmez	Chairman	msonmez@burgan.com.tr	+90 212 371 3431
Zafer Onat	CEO	zafer.onat@burgansecurities.com	+90 212 317 2867

INSTITUTIONAL SALES (sales@burgansecurities.com)

Tolga Atac	Head of Sales & Trading	tolga.atac@burgansecurities.com	+90 212 317 2770
Can Yazgan	Head of Sales	can.yazgan@burgansecurities.com	+90 212 317 2757
Yilmaz Manisali	Sales	yilmaz.manisali@burgansecurities.com	+90 212 317 2878
Cansev Sanli	Sales	cansev.sanli@burgansecurities.com	+90 212 317 2860
Canan Uras	Sales & Trading	canan.uras@burgansecurities.com	+90 212 317 2825
Aysegul Yilmaz	Sales & Trading	aysegul.yilmaz@burgansecurities.com	+90 212 317 2759
Burak Demircioglu	Sales & Trading	burak.demircioglu@burgansecurities.com	+90 212 317 2765

EQUITY RESEARCH (e.research@burgansecurities.com)

Nergis Kasabali	Banking & Head of Research	nergis.kasabali@burgansecurities.com	+90 212 317 2753
Burak Isyar, CFA	Retail, Beverages, Automotive, Consumer Durables, Aviation	burak.isyar@burgansecurities.com	+90 212 317 2709
Murat Ignebekcili	Telecom, Construction, Real Estate, Utilities, Conglomerates	murat.ignebekcili@burgansecurities.com	+90 212 317 2761
Duygun Kutucu, CFA	Banking	duygun.kutucu@burgansecurities.com	+90 212 317 2784
Umut Ozturk	Oil & Gas, Steel, Fertilizers, Mid-Cap Autos	umut.ozturk@burgansecurities.com	+90 212 317 2703
Ece Mandaci	Mining, Glass, Cement, Small Caps	ece.mandaci@burgansecurities.com	+90 212 317 2738
Ismail Ozer	Quantitative Analysis	ismail.ozter@burgansecurities.com	+90 212 317 2705
Nuray Apari	Senior Database Manager	nuray.apari@burgansecurities.com	+90 212 317 2707
Lolita Haleva	Editor	lolita.haleva@burgansecurities.com	+90 212 317 2704

MACROECONOMIC RESEARCH (m.research@burgansecurities.com)

Haluk Burumcekci	Chief Economist	haluk.burumcekci@burgansecurities.com	+90 212 317 2737
Asli Savranoglu	Senior Economist	asli.savranoglu@burgansecurities.com	+90 212 317 2866

Burgan Yatirim Menkul Degerler Anonim Sirketi ("Burgan Securities"). All rights reserved.

Burgan Securities holds the required licences (Financial Intermediation Licence Number: 346; Licence Date: 10.06.2005), and operates under the supervision of the CMB and in line with the CMB regulations. The research reports have been prepared by Burgan Securities solely for informational purposes. The receipt of the research reports should not be construed, under any circumstances, as a solicitation to purchase or sell equities or as a determination of the suitability of any investment for any particular recipient, or as any offer of any nature. The information contained in the research reports has been produced by Burgan Securities and obtained by external sources believed to be reliable, which Burgan Securities attempts to verify but neither represents nor warrants in any way its accuracy or completeness. The information and expressions of opinion stated in the research reports are inherently subject to change without notice and may become outdated. Information, text and graphics of the research reports may include technical inaccuracies or typographical errors. This information is provided without any representation or warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability, fitness for a particular purpose, and non-infringement, and it is entirely your responsibility to verify any information before relying on it, and decisions based on information contained in the research reports are your sole responsibility. Under any circumstances, neither Burgan Securities nor any of its parents, subsidiaries or affiliates, agents, or representatives shall be liable to any party for any direct, indirect, special, incidental, consequential, punitive, or exemplary damages, including without limitation lost profits (even if expressly advised of the possibility) arising in any way from the information contained in the research reports. All information provided in the research reports is for non-commercial internal use; you may not reproduce, retransmit, distribute, disseminate, sell, publish, broadcast or circulate the information to anyone, without the express written consent of Burgan Securities.

Burgan Securities does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.